Merck (MRK) Tops Q2 EPS by 12c, Beats on Revenue; Offers FY24 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Merck (MRK) tops earnings, revenue expectations but guidance mixed
July 30, 2024 6:49 AM EDT(Updated - July 30, 2024 10:02 AM EDT)
Merck (NYSE: MRK) reported a robust second quarter, with adjusted earnings per share (EPS) of $2.28, surpassing analysts' predictions by $0.12. The pharmaceutical giant also exceeded revenue expectations, posting $16.11 billion against a $15.85 billion consensus.
However, the company's stock has fallen by more than 6% following the report.
The company's chairman and CEO, Robert Davis, attributed the strong quarterly performance to "excellent scientific, commercial and operational execution," highlighting the successful U.S. launch of WINREVAIR and positive European opinions for adults with pulmonary... More
